Janssen expands EXPLORER global cardiovascular program to evaluate role of XARELTO(R)
Janssen R&D and partner, Bayer HealthCare, announced the expansion of the EXPLORER global cardiovascular research program for XARELTO® (rivaroxaban) to include additional high-risk patient populations. New trials will investigate rivaroxaban, the most studied Factor Xa inhibitor for ACS treatment. August 29, 2014